标题
Selinexor for the treatment of multiple myeloma
作者
关键词
-
出版物
EXPERT OPINION ON PHARMACOTHERAPY
Volume 21, Issue 4, Pages 399-408
出版商
Informa UK Limited
发表日期
2020-01-20
DOI
10.1080/14656566.2019.1707184
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Selinexor, Pomalidomide, and Dexamethasone (SPd) in Patients with Relapsed or Refractory Multiple Myeloma
- (2020) Christine I Chen et al. BLOOD
- Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma
- (2019) Andrzej J. Jakubowiak et al. BRITISH JOURNAL OF HAEMATOLOGY
- A phase I clinical study to evaluate the safety, tolerability, pharmacokinetics (PK), and antitumor activity of FN-1501 monotherapy in patients with advanced solid tumors.
- (2019) Gary Edward Richardson et al. JOURNAL OF CLINICAL ONCOLOGY
- A Phase II Trial of Selinexor (KPT‐330) for Metastatic Triple‐Negative Breast Cancer
- (2019) Michael Shafique et al. ONCOLOGIST
- Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial
- (2019) Paul G Richardson et al. LANCET ONCOLOGY
- Selinexor in combination with decitabine in patients with acute myeloid leukemia: results from a phase 1 study
- (2019) Bhavana Bhatnagar et al. LEUKEMIA & LYMPHOMA
- Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma
- (2019) Ajai Chari et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Phase 1b/2 Study of Selinexor, Carfilzomib, and Dexamethasone (SKd) in Relapsed/ Refractory Multiple Myeloma (RRMM)
- (2019) Cristina Gasparetto et al. BLOOD
- Safety and Efficacy of the Combination of Selinexor, Lenalidomide and Dexamethasone (SRd) in Patients with Newly Diagnosed Multiple Myeloma
- (2019) Darrell J White et al. BLOOD
- The Result of a Phase 1 Study of Selinexor in Combination with High-Dose Melphalan and Autologous Hematopoietic Cell Transplantation for Multiple Myeloma
- (2019) Taiga Nishihori et al. BLOOD
- Influence of Cytogenetics in Patients with Relapsed Refractory Multiple Myeloma Treated with Oral Selinexor and Dexamethasone: A Post-Hoc Analysis of the STORM Study
- (2019) Ajay K Nooka et al. BLOOD
- Selinexor-Containing Regimens for the Treatment of Patients with Multiple Myeloma Refractory to Chimeric Antigen Receptor T-Cell (CAR-T) Therapy
- (2019) Ajai Chari et al. BLOOD
- Overall Survival of Triple Class Refractory, Penta-Exposed Multiple Myeloma (MM) Patients Treated with Selinexor Plus Dexamethasone or Conventional Care: A Combined Analysis of the STORM and Mammoth Studies
- (2019) Luciano J. Costa et al. BLOOD
- Response to Therapy and the Effectiveness of Treatment with Selinexor and Dexamethasone in Patients with Penta-Exposed Triple-Class Refractory Myeloma Who Had Plasmacytomas
- (2019) Andrew J. Yee et al. BLOOD
- Daratumumab resistance is frequent in advanced-stage multiple myeloma patients irrespective of CD38 expression and is related to dismal prognosis
- (2018) Marjorie Pick et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma
- (2018) Dan T. Vogl et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase I study of selinexor in combination with high-dose cytarabine and mitoxantrone for remission induction in patients with acute myeloid leukemia
- (2018) Amy Y. Wang et al. Journal of Hematology & Oncology
- A Phase II Trial of Selinexor, an Oral Selective Inhibitor of Nuclear Export Compound, in Abiraterone‐ and/or Enzalutamide‐Refractory Metastatic Castration‐Resistant Prostate Cancer
- (2018) Xiao X. Wei et al. ONCOLOGIST
- Selinexor synergizes with dexamethasone to repress mTORC1 signaling and induce multiple myeloma cell death
- (2018) Christian Argueta et al. Oncotarget
- Anti-tumor efficacy of Selinexor (KPT-330) in gastric cancer is dependent on nuclear accumulation of p53 tumor suppressor
- (2018) Vinod Vijay Subhash et al. Scientific Reports
- Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma
- (2018) Nizar J. Bahlis et al. BLOOD
- Nuclear-cytoplasmic transport is a therapeutic target in myelofibrosis
- (2018) Dongqing Yan et al. CLINICAL CANCER RESEARCH
- Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study
- (2017) S K Kumar et al. LEUKEMIA
- Cytoplasmic cyclin D1 controls the migration and invasiveness of mantle lymphoma cells
- (2017) Simon Body et al. Scientific Reports
- Selinexor (KPT-330) has antitumor activity against anaplastic thyroid carcinoma in vitro and in vivo and enhances sensitivity to doxorubicin
- (2017) Manoj Garg et al. Scientific Reports
- Recurrent mutations of the exportin 1 gene (XPO1) and their impact on selective inhibitor of nuclear export compounds sensitivity in primary mediastinal B-cell lymphoma
- (2016) Fabrice Jardin et al. AMERICAN JOURNAL OF HEMATOLOGY
- CRM1 Inhibition Promotes Cytotoxicity in Ewing Sarcoma Cells by Repressing EWS-FLI1-Dependent IGF-1 Signaling
- (2016) H. Sun et al. CANCER RESEARCH
- Inhibition of the Nuclear Export Receptor XPO1 as a Therapeutic Target for Platinum-Resistant Ovarian Cancer
- (2016) Ying Chen et al. CLINICAL CANCER RESEARCH
- The Second-Generation Exportin-1 Inhibitor KPT-8602 Demonstrates Potent Activity against Acute Lymphoblastic Leukemia
- (2016) Thomas Vercruysse et al. CLINICAL CANCER RESEARCH
- Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Combination With Fludarabine and Cytarabine, in Pediatric Relapsed or Refractory Acute Leukemia
- (2016) Thomas B. Alexander et al. JOURNAL OF CLINICAL ONCOLOGY
- First-in-Class, First-in-Human Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Patients With Advanced Solid Tumors
- (2016) Albiruni R. Abdul Razak et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase IB Study of Selinexor, a First-in-Class Inhibitor of Nuclear Export, in Patients With Advanced Refractory Bone or Soft Tissue Sarcoma
- (2016) Mrinal M. Gounder et al. JOURNAL OF CLINICAL ONCOLOGY
- Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors
- (2016) Joel G. Turner et al. Journal of Hematology & Oncology
- Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial
- (2016) Sagar Lonial et al. LANCET
- KPT-8602, a second-generation inhibitor of XPO1-mediated nuclear export, is well tolerated and highly active against AML blasts and leukemia-initiating cells
- (2016) J Etchin et al. LEUKEMIA
- Next-generation XPO1 inhibitor shows improved efficacy and in vivo tolerability in hematological malignancies
- (2016) Z A Hing et al. LEUKEMIA
- Heterozygous mutation of cysteine528 in XPO1 is sufficient for resistance to selective inhibitors of nuclear export
- (2016) Jasper Edgar Neggers et al. Oncotarget
- Selinexor, a Selective Inhibitor of Nuclear Export (SINE) compound, acts through NF-κB deactivation and combines with proteasome inhibitors to synergistically induce tumor cell death
- (2016) Trinayan Kashyap et al. Oncotarget
- XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma
- (2016) Joel G. Turner et al. Oncotarget
- Identifying Drug-Target Selectivity of Small-Molecule CRM1/XPO1 Inhibitors by CRISPR/Cas9 Genome Editing
- (2015) Jasper E. Neggers et al. CHEMISTRY & BIOLOGY
- Molecular Pathways: Anticancer Activity by Inhibition of Nucleocytoplasmic Shuttling
- (2015) F. Conforti et al. CLINICAL CANCER RESEARCH
- Synergistic Myeloma Cell Death via Novel Intracellular Activation of Caspase-10-Dependent Apoptosis by Carfilzomib and Selinexor
- (2015) S. Rosebeck et al. MOLECULAR CANCER THERAPEUTICS
- Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma
- (2015) Henk M. Lokhorst et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting nucleocytoplasmic transport in cancer therapy
- (2015) Richard Hill et al. Oncotarget
- Selective inhibitors of nuclear export (SINE) as novel therapeutics for prostate cancer
- (2015) Janet Mendonca et al. Oncotarget
- KPT-330 has antitumour activity against non-small cell lung cancer
- (2014) H Sun et al. BRITISH JOURNAL OF CANCER
- Meta-Analysis of the Efficacy and Safety of Bortezomib Re-Treatment in Patients With Multiple Myeloma
- (2014) Kevin B. Knopf et al. Clinical Lymphoma Myeloma & Leukemia
- XPO1/CRM1-Selective Inhibitors of Nuclear Export (SINE) reduce tumor spreading and improve overall survival in preclinical models of prostate cancer (PCa)
- (2014) Giovanni Gravina et al. Journal of Hematology & Oncology
- Nucleo-cytoplasmic transport as a therapeutic target of cancer
- (2014) Giovanni Luca Gravina et al. Journal of Hematology & Oncology
- Selective inhibitors of nuclear export (SINE)– a novel class of anti-cancer agents
- (2014) Kaushal Parikh et al. Journal of Hematology & Oncology
- XPO1 (CRM1) Inhibition Represses STAT3 Activation to Drive a Survivin-Dependent Oncogenic Switch in Triple-Negative Breast Cancer
- (2014) Y. Cheng et al. MOLECULAR CANCER THERAPEUTICS
- Inhibition of CRM1-dependent nuclear export sensitizes malignant cells to cytotoxic and targeted agents
- (2014) Joel G. Turner et al. SEMINARS IN CANCER BIOLOGY
- Clinical translation of nuclear export inhibitors in cancer
- (2014) William T. Senapedis et al. SEMINARS IN CANCER BIOLOGY
- Promising SINEs for Embargoing Nuclear-Cytoplasmic Export as an Anticancer Strategy
- (2014) D. S. P. Tan et al. Cancer Discovery
- Prognostic impact and targeting of CRM1 in acute myeloid leukemia
- (2013) K. Kojima et al. BLOOD
- Preclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph+ leukemias
- (2013) C. J. Walker et al. BLOOD
- KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia
- (2013) Julia Etchin et al. BRITISH JOURNAL OF HAEMATOLOGY
- Genome-wide studies in multiple myeloma identify XPO1/CRM1 as a critical target validated using the selective nuclear export inhibitor KPT-276
- (2013) J Schmidt et al. LEUKEMIA
- CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications
- (2013) Y-T Tai et al. LEUKEMIA
- CRM1 and BRAF Inhibition Synergize and Induce Tumor Regression in BRAF-Mutant Melanoma
- (2013) R. A. Salas Fragomeni et al. MOLECULAR CANCER THERAPEUTICS
- Nuclear export inhibition through covalent conjugation and hydrolysis of Leptomycin B by CRM1
- (2013) Qingxiang Sun et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy
- (2012) M. Chesi et al. BLOOD
- Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia
- (2012) R. Lapalombella et al. BLOOD
- Reversible targeting of noncatalytic cysteines with chemically tuned electrophiles
- (2012) Iana M Serafimova et al. Nature Chemical Biology
- The Oncogene eIF4E Reprograms the Nuclear Pore Complex to Promote mRNA Export and Oncogenic Transformation
- (2012) Biljana Culjkovic-Kraljacic et al. Cell Reports
- CBS9106 is a novel reversible oral CRM1 inhibitor with CRM1 degrading activity
- (2011) K. Sakakibara et al. BLOOD
- NOTCH1 mutations in CLL associated with trisomy 12
- (2011) V. Balatti et al. BLOOD
- Identification of Molecular Vulnerabilities in Human Multiple Myeloma Cells by RNA Interference Lethality Screening of the Druggable Genome
- (2011) R. E. Tiedemann et al. CANCER RESEARCH
- The eukaryotic translation initiation factor 4E (eIF4E) and HuR RNA operons collaboratively regulate the expression of survival and proliferative genes
- (2011) Ivan Topisirovic et al. CELL CYCLE
- Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study
- (2011) S K Kumar et al. LEUKEMIA
- Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia
- (2011) Xose S. Puente et al. NATURE
- Human Multiple Myeloma Cells Are Sensitized to Topoisomerase II Inhibitors by CRM1 Inhibition
- (2009) J. G. Turner et al. CANCER RESEARCH
- Identification of Nuclear Export Inhibitors with Potent Anticancer Activity In vivo
- (2009) S. C. Mutka et al. CANCER RESEARCH
- EXPRESSION OF CRM1 IN HUMAN GLIOMAS AND ITS SIGNIFICANCE IN P27 EXPRESSION AND CLINICAL PROGNOSIS
- (2009) Aiguo Shen et al. NEUROSURGERY
- Expression of the nuclear export protein chromosomal region maintenance/exportin 1/Xpo1 is a prognostic factor in human ovarian cancer
- (2008) Aurelia Noske et al. CANCER
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now